From:UBS



**UBS AG** 

Singapore Branch One Raffles Quay #50-01 North Tower Singapore 048583 Tel. +65 6495 8000

Group Risk Control

19 April 2018

Τo,

The BSE Limited  Department of Corporate Services  1st Floor, New Trading Ring  Rotunda Building, P.J. Towers  Dalal Street, Fort	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E) Mumbai 400 051, India Attn: Listing Department
Mumbai 400 001, India Fortis Healthcare Limited	
Fortis Hospital   Sector 62,Phase VIII,	
Mohali, Punjab – 160062, India	

Sub: Disclosure of interest pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011

Dear Sir/Madam,

Please find attached, a disclosure of shareholdings under Regulation 29 (1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This disclosure is being filed in relation to acquisition of shares amounting to 5.21% of the share capital carrying voting rights in Fortis Healthcare Limited.

Kindly contact Philip Alexander at +85 229716074 should you have any queries in relation to this matter.

Yours sincerely, UBS Group AG

Philip Alexander

Group Risk Control

## Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

## Part -A- Details of the Acquisition

From:UBS

Name of the Target Company (TC)	Fortis Healthcare Limited		
Name(s) of the acquirer and Persons	UBS PRINCIPAL CAPITAL ASIA LTD		
Acting in Concert (PAC) with the			
acquirer			
Whether the acquirer belongs to	No		
Promoter/Promoter group			
Name(s) of the Stock Exchange(s)	BSE Limited and the National Stock		
where the shares of TC are Listed	Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under			
consideration, holding of acquirer			
along with PACs of:			
a) Shares carrying voting rights	24,818,455	4.78% NIL	4.78%   NIL
b) Shares in the nature of	NIL	NIL	NIL
encumbrance (pledge/ lien/non-			
disposal undertaking/ others)		NIL	NIL
c) Voting rights (VR) otherwise than	NIL	"""	
by equity shares		NIL	NIL
d) Warrants/convertible	NIL		'''-
securities/any other instrument			
that entitles the acquirer to			
receive shares carrying voting			
rights in the TC (specify holding			
in each category)			
e) Total (a+b+c+d)	24,818,455	4.78%	4.78%

From:UBS

Det	ails of acquisition			
a)	Shares carrying voting rights acquired	2,220,934	0.43%	0.43%
b)	VRs acquired otherwise than by	NIL	NIL	NIL
	equity shares			
c)	Warrants/convertible	NIL	NIL	NIL
	securities/any other instrument			
	that entitles the acquirer to			
	receive shares carrying voting			
	rights in the TC (specify holding			
	in each category) acquired.			
d)	Shares in the nature of	NIL	NIL	NIL
	encumbrance (pledge/ lien/non-			
	disposal undertaking/ others)			
e)	Total (a+b+c+/-d)	2,220,934	0.43%	0.43%
Afte	er the acquisition, holding of			
acq	uirer along with PACs of:			
a)	Shares carrying voting rights	27,039,389	5.21% NIL	5.21% NIL
b)	VRs otherwise than by equity	NIL	NIL	NIL
	shares		NIL	NIL
c)	Warrants/convertible	NIL	NIL	NIE
	securities/any other instrument			
	that entitles the acquirer to			
	receive shares carrying voting			
	rights in the TC (specify holding			
	in each category) after			
	acquisition		NIL	NIL
d)	Shares in the nature of	NIL	- 3	<del>-</del>
	encumbrance (pledge/ lien/ non-			
-1	disposal undertaking/ others)	27 020 222	E 040/	E 240/
e)	Total (a+b+c+d)	27,039,389	5.21%	5.21%

From:UBS

Mode of acquisition (e.g. open	Open Market
market/ <del>public issue</del> / <del>rights issue</del>	
/preferential allotment / inter-se	
transfer/ encumbrance etc.)	
Salient features of the securities	Not Applicable
acquired including time till	
redemption, ratio at which it can be	
converted into equity shares etc.	
Date of acquisition of/ date of receipt	17-Apr-2018
of intimation of allotment of	
shares/VR/ warrants/convertible	
coouritiec/any other inctrument that	
entitles the acquirer to receive shares	
in the TC.	
Equity share capital / total voting	518,677,231 (As per NSE)
capital of the TC before the said	
acquisition	
Equity share capital/ total voting	518,677,231 (As per NSE)
capital of the TC after the said	
acquisition	
Total diluted share/voting capital of	518,677,231 (As per NSE)
the TC after the said acquisition	

## To: From: UBS

Signature of the acquirer / Authorised Signatory

Philip Alexander Group Risk Control

P. Homosor

Place: UBS AG, Singapore Branch

Date: 19 April 2018

## Note:

- (\*)Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.
- (\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.